预先存在的体液免疫和 CD4 T 细胞反应与异源初免-加强接种后对 SARS-CoV-2 奥密克戎亚变种的交叉反应相关。
Pre-existing humoral immunity and CD4 T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination.
机构信息
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC.
出版信息
Clin Immunol. 2023 Jun;251:109342. doi: 10.1016/j.clim.2023.109342. Epub 2023 Apr 24.
BACKGROUND
Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination.
METHODS
We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay.
RESULTS
All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4 T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender.
CONCLUSIONS
A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4 T cells response correlates with post-booster neutralization reactivity against the Omicron variant.
背景
关于异源加强 COVID 疫苗接种的信息已经得到充分阐明。本研究旨在评估异源疫苗接种后体液、细胞免疫和对变体的交叉反应性。
方法
我们招募了先前接受牛津/阿斯利康 ChAdOx1-S 疫苗初级免疫和 Moderna mRNA-1273 疫苗加强针的医护人员，以评估免疫反应。使用的检测方法：抗刺突 RBD 抗体、替代病毒中和抗体和干扰素-γ释放试验。
结果
无论先前的抗体水平如何，所有参与者在加强针后均表现出更高的体液和细胞免疫反应，但抗体水平较高的参与者表现出更强的加强针反应，尤其是针对奥密克戎 BA.1 和 BA.2 变体。调整年龄和性别后，CD4 T 细胞的预加强 IFN-γ 释放与 BA.1 和 BA.2 变体的后加强中和抗体呈正相关。
结论
异源 mRNA 加强针具有高度的免疫原性。预先存在的中和抗体水平和 CD4 T 细胞反应与奥密克戎变体的后加强中和反应性相关。
Zotero 插件